Jordánsko - angličtina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - hydrochlorothiazide 12.5 mg, valsartan 160 mg - 12.5 mg, 160 mg

Izrael - angličtina - Ministry of Health

novartis israel ltd - secukinumab - solution for injection - secukinumab 150 mg/ml - secukinumab - - plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. - paediatric plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. - psoriatic arthritis: cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (dmard) therapy has been inadequate. - axial spondyloarthritis (axspa) : •ankylosing spondylitis (as, radiographic axial spondyloarthritis) cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. •non-radiographic axial spondyloarthritis (nr-axspa) cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (nsaids). - juvenile idiopathic arthritis (jia) •enthesitis-related arthritis (era) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitisrelated arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. •juvenile psoriatic arthritis (jpsa) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy

Jordánsko - angličtina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - imatinib 100 mg - 100 mg

Jordánsko - angličtina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - imatinib 400 mg - 400 mg

Jordánsko - angličtina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - paroxetine 20 mg - 20 mg

Jordánsko - angličtina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة المتحدة لصناعة الأدوية - united pharmaceutical manufacturing co. ltd. - roflumilast 500 mcg - 500 mcg

Jordánsko - angličtina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع خوري - khoury drug store - methylprednisolone 40 mg - 40 mg

Jordánsko - angličtina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع خوري - khoury drug store - methylprednisolone 500 mg - 500 mg

Jordánsko - angličtina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع خوري - khoury drug store - methylprednisolone 1000 mg - 1000 mg

Jordánsko - angličtina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة العربية لصناعة الادوية المساهمة الخاصة - the arab pharmaceutical manufacturing psc - pioglitazone 30 mg - 30 mg